Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fludarabine therapy in Waldenstrom's macroglobulinemia
Autore:
Thalhammer-Scherrer, R; Geissler, K; Schwarzinger, I; Chott, A; Gisslinger, H; Knobl, P; Lechner, K; Jager, U;
Indirizzi:
Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, AustriaUniv Vienna Vienna Austria A-1090 & Hemostaseol, A-1090 Vienna, Austria Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 , Dept Lab Med, A-1090 Vienna, Austria Univ Vienna, Dept Clin Pathol, A-1090 Vienna, Austria Univ Vienna ViennaAustria A-1090 pt Clin Pathol, A-1090 Vienna, Austria
Titolo Testata:
ANNALS OF HEMATOLOGY
fascicolo: 10, volume: 79, anno: 2000,
pagine: 556 - 559
SICI:
0939-5555(200010)79:10<556:FTIWM>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC LYMPHOCYTIC-LEUKEMIA; LOW-GRADE LYMPHOMA; PHASE-II; SINGLE-AGENT; CLASSIFICATION; PHOSPHATE;
Keywords:
fludarabine therapy; Waldenstrom's macroglobulinemia;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Jager, U Univ Vienna, Dept Med 1, Div Hematol & Hemostaseol, Waehringer Guertel 18-20, A-1090 Vienna, Austria Univ Vienna Waehringer Guertel 18-20 Vienna Austria A-1090 stria
Citazione:
R. Thalhammer-Scherrer et al., "Fludarabine therapy in Waldenstrom's macroglobulinemia", ANN HEMATOL, 79(10), 2000, pp. 556-559

Abstract

Seven patients with macroglobulinemia (six previously untreated, one with minimal pretreatment) were treated with fludarabine (25 mg/m(2)/day for 5 days, repeated every 4 weeks). The median age was 58 years. The time from diagnosis to treatment with fludarabine was 4.5 months to 175 months (median 32.6 months). The patients received six (n =5), five (n =1), and three (n =1) courses of fludarabine. One patient showed only a slight decrease of immunoglobulin (Ig) M (from 5750 mg/dl to 4700 mg/dl) and no improvement of anemia. Therefore, treatment was stopped after three cycles. In the other sixpatients, a marked reduction of IgM levels (from 6140 mg/dl to 1220 mg/dl median), a normalization of hemoglobin (from 10.8 g/dl to 12.3 g/dl median), a reduction of lymphocyte count (from 1992/mul to 652/mul median), and a reduction of beta2 microglobulin (from 2.3 mg/l to 1.8 mg/l median) were achieved. A 50% IgM reduction was achieved 5.4 months (median) after the beginning of therapy, and the maximum response was observed 17.3 months (median) after the end of treatment. The responses were sustained without further therapy in six patients for 20.8-55.2 months. In one patient, disease progression was observed 12.5 months after the end of therapy. Fludarabine therapy was well tolerated with few side effects. In three patients, febrile episodes occurred. No opportunistic infections were recorded. We conclude thatfludarabine is an effective treatment in previously untreated or in minimally pretreated patients with Waldenstrom's macroglobulinemia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 00:59:59